KFAS
LGND icon

Keating Financial Advisory Services’s Ligand Pharmaceuticals LGND Stock Holding History

Keating Financial Advisory Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.8K Buy
31
+1
+3% +$236 ﹤0.01% 1255
2026
Q1 		$5.99K Buy
30
+22
+275% +$4.35K ﹤0.01% 1346
2025
Q4 		$1.51K Buy
+8
New +$1.54K ﹤0.01% 1673

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's LGND Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Ligand Pharmaceuticals (LGND) stake by 3.3% in Q2 2026, buying an estimated $236 and bringing the position to 31 shares worth $9.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Keating Financial Advisory Services first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 415 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Keating Financial Advisory Services held 31 shares of Ligand Pharmaceuticals worth $9.8K as of Q2 2026.
  • Keating Financial Advisory Services bought 1 Ligand Pharmaceuticals share in Q2 2026, an estimated $236.
  • Ligand Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1255 holding.
  • Keating Financial Advisory Services first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 415 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.